{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:34:19Z","timestamp":1791221659881,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.bcmd.2012.10.005","type":"journal-article","created":{"date-parts":[[2012,11,12]],"date-time":"2012-11-12T07:02:26Z","timestamp":1352703746000},"page":"119-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7 + 3"],"prefix":"10.1016","volume":"50","author":[{"given":"Marshall A.","family":"Lichtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2012.10.005_bb0005","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1001\/jama.296.12.1518","article-title":"An anniversary for cancer chemotherapy","volume":"296","author":"Hirsch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0015","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1950.02920160023005","article-title":"Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias","volume":"144","author":"Pearson","year":"1950","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0020","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJM198704233161702","article-title":"Benzene and leukemia. An epidemiologic risk assessment","volume":"316","author":"Rinsky","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.yrtph.2009.08.008","article-title":"Characterization of cancer risk from airborne benzene exposure","volume":"55","author":"Johnson","year":"2009","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0030","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/sj.leu.2404698","article-title":"Cigarette smoking, cytogenetic abnormalities, and acute myelogenous leukemia","volume":"21","author":"Lichtman","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0035","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1634\/theoncologist.2010-0206","article-title":"Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma","volume":"15","author":"Lichtman","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0040","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1136\/bmj.1.5500.1383","article-title":"Council; Treatment of acute leukemia in adults: comparison of steroid and mercaptopurine therapy alone and in conjunction","volume":"1","author":"Party","year":"1966","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/jama.1965.03090020019005","article-title":"Causes of death in acute leukemia","volume":"193","author":"Hersh","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0050","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM196205032661802","article-title":"The quantitative relation between platelet count and hemorrhage in patients with acute leukemia","volume":"266","author":"Gaydos","year":"1962","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/archinte.1965.03870020106019","article-title":"Multiple organism septicemia in acute leukemia: analysis of 54 episodes","volume":"116","author":"Bodey","year":"1965","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V26.2.220.220","article-title":"Therapy of acute leukemia","volume":"26","author":"Dameshek","year":"1965","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0065","first-page":"871","article-title":"Effects of combinations of antileukemic agents on an acute lymphocytic leukemia in mice","volume":"12","author":"Law","year":"1952","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0070","first-page":"631","article-title":"Combined treatment of advanced leukemia (L1210) in mice with amethopterin and 6-mercaptopurine","volume":"17","author":"Goldin","year":"1956","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0075","first-page":"203","article-title":"Modification of treatment schedules ion the management of advanced mouse leukemia with Amethopterin","volume":"17","author":"Goldin","year":"1956","journal-title":"J. Nat. Cancer Inst."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0080","first-page":"1","article-title":"Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with \u201ccurability\u201d of experimental leukemia","volume":"35","author":"Skipper","year":"1964","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0085","first-page":"276","article-title":"The transmission of leukaemia of mice with a single cell","volume":"31","author":"Furth","year":"1937","journal-title":"Am. J. Cancer"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0090","first-page":"9","article-title":"Legacy and History of Roswell Park Cancer Institute 1898\u20131998","author":"Mirand","year":"1998"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0095","first-page":"255a","article-title":"Isotope derivative assay of aldosterone in biological extracts","volume":"17","author":"Kliman","year":"1958","journal-title":"Fed. Proc."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0100","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1210\/jcem-24-7-638","article-title":"Studies on phenolic steroids in human subjects. VI. Biosynthesis of estriolglucosiduronic acid-16-14C by human liver","volume":"24","author":"Slaunwhite","year":"1964","journal-title":"J. Clin. Endocrinol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0105","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/1097-0142(19840515)53:10<2013::AID-CNCR2820531003>3.0.CO;2-2","article-title":"Acute leukemia in children. Model for the development of scientific methodology for clinical therapeutic research in cancer","volume":"53","author":"Frei","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0110","series-title":"Proceedings of the sixth International Congress of the International Society of Hematology, Boston, August 27-September 1, 1956","first-page":"213","article-title":"Criteria for remission in acute leukemia","author":"Holland","year":"1958"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0115","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V13.12.1126.1126","article-title":"A comparative study of two regimens of combination chemotherapy in acute leukemia","volume":"13","author":"Frei","year":"1958","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-1-4831-9930-6.50008-3","article-title":"Metabolic basis for the actions of analogs of purines and pyrimidines","volume":"2","author":"Elion","year":"1965","journal-title":"Adv. Chemother."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0125","first-page":"1","volume":"78","author":"Avery","year":"2000"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0130","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1039\/JR9560002388","article-title":"Nucleosides. The structure of uridylic acids a and b, and synthesis of spongouridine (3-\u03b2-D-arabinofuranosyluracil)","volume":"37","author":"Brown","year":"1956","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0135","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1021\/ja01568a030","article-title":"Pyrimidine Nucleosides. II. The synthesis of 1-\u03b2-D-arabinofuranosylthymine (spongothymidine)","volume":"79","author":"Fox","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0140","first-page":"84","article-title":"Cyclisation During The Phosphorylation Of Uridine And Cytidine By Polyphosphoric Acid - A New Route To The O-2,2'-Cyclonucleosides","volume":"3","author":"Walwick","year":"1959","journal-title":"Proc. Chem. Soc. (Lond.)"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0145","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/S0021-9258(18)64632-0","article-title":"Metabolism of pyrimidine arabinonucleosides and cyclonucleosides in Escherichia coli","volume":"235","author":"Pizer","year":"1960","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0150","first-page":"357a","article-title":"Effect of arabinonucleosides on growth and metabolism of E. coli","volume":"20","author":"Schlecta","year":"1961","journal-title":"Fed. Proc."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0155","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3181\/00379727-106-26335","article-title":"Antitumor activity of 1-\u03b2-D-arainofuranosylcytosine hydrochloride","volume":"106","author":"Evans","year":"1961","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0160","first-page":"65","article-title":"Activity of cytosine arabinoside (NSC-63878) in a spectrum of rodent tumors","volume":"47","author":"Wodinsky","year":"1965","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0165","first-page":"1285","article-title":"The effect of 1-\u03b2-D-arabinofuranosylcytosine hydrochloride on murine neoplasms","volume":"24","author":"Evans","year":"1964","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0006-2952(62)90225-3","article-title":"A proposed mechanism of action of 1-\u03b2-D-arabinofuranosyl-cytosine as an inhibitor of the growth of leukemic cells","volume":"11","author":"Chu","year":"1962","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0175","first-page":"50a","article-title":"Clinical and pharmacological studies with 1-b-D-arabinofuranosylcytosine (cytosine arabinoside)","volume":"6","author":"Papac","year":"1965","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0180","first-page":"11","article-title":"Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC-63878)","volume":"48","author":"Dixon","year":"1965","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0185","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0006-2952(65)90175-9","article-title":"Studies on the enzymatic deamination of cytosine arabinoside. I Enzyme distribution and species specificity","volume":"14","author":"Caminier","year":"1965","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0190","first-page":"1930","article-title":"Chemotherapy of leukemia L1210 in mice with 1-\u03b2-D-arabinofuranosylcytosine hydrochloride. II. Effectiveness against intercerebrally and subcutaneously inoculated leukemic cells","volume":"26","author":"Kline","year":"1966","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0195","first-page":"853","article-title":"Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules","volume":"26","author":"Kline","year":"1966","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0200","series-title":"Toxicity of U-19, 920A; Confidential report","author":"Johnston","year":"1960"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0205","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood.V21.3.352.352","article-title":"Megaloblastosis produced by a cytosine antagonist:1-b-D-arabinofuranosylcytosine","volume":"21","author":"Talley","year":"1963","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0210","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood.V5.8.695.695","article-title":"Studies on the relationships of vitamin B12, folic acid, thymine, uracil and methyl group donors in persons with pernicious anemia and related megaloblastic anemias","volume":"5","author":"Vilter","year":"1950","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0215","first-page":"125","article-title":"Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells","volume":"51","author":"Skipper","year":"1967","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0220","first-page":"2573","article-title":"Therapy for acute granulocytic leukemia","volume":"27","author":"Freireich","year":"1967","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0225","series-title":"Proceedings of the Ninth International Cancer Congress, Tokyo","article-title":"Cytosine arabinoside: a new agent for induction of remission in acute leukemia","author":"Ellison","year":"1966"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0230","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/cpt196786800","article-title":"Continuous infusion of arabinosyl cytosine in patients with neoplastic disease","volume":"8","author":"Ellison","year":"1967","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0235","first-page":"799","article-title":"Un nouvel agent actif dans traitment des leucemies aigue","volume":"74","author":"Bernard","year":"1966","journal-title":"Presse Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0240","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V32.4.507.507","article-title":"Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults","volume":"32","author":"Ellison","year":"1968","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0245","first-page":"29a","article-title":"Cytosine arabinoside infusions in adult and childhood acute myelocytic leukemia","volume":"9","author":"Henderson","year":"1968","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0250","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/0003-4819-69-3-628","article-title":"Treatment of acute leukemia","volume":"69","author":"Henderson","year":"1968","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0255","first-page":"271","article-title":"Treatment of acute leukemia","volume":"6","author":"Henderson","year":"1969","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0260","first-page":"65","article-title":"Methyl-GAG in patients with malignant neoplasms: a phase I re-evaluation","volume":"66","author":"Hart","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0265","first-page":"649","article-title":"The Nobel Prize Winners","volume":"vol. 2","author":"Waxman","year":"1944"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0270","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3181\/00379727-45-11768","article-title":"Bacteriostatic and bactericidal substances produced by a soil actinomyces","volume":"45","author":"Waksman","year":"1940","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0275","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1749-6632.1960.tb20151.x","article-title":"The actinomycins and their importance in the treatment of tumors in animals and man","volume":"89","author":"Waksman","year":"1960","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0280","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF00623151","article-title":"Rhodomycin, ein rotes Antibioticum aus Actinomyceten","volume":"37","author":"Brockmann","year":"1950","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0285","first-page":"121","article-title":"Anthracyclinone und Anthracycline (rhodomycinone, pyrromycinone und ihre glucoside)","volume":"21","author":"Brockmann","year":"1963","journal-title":"Fortschr. Chem. Org. Naturst."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0290","first-page":"1813","article-title":"Un nouvel antibiotique \u00e0 propri\u00e9t\u00e9s cytostatiques; la rubidomycine","volume":"257","author":"Dubost","year":"1963","journal-title":"C. R."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0295","first-page":"167","article-title":"La daunomicina - un nuovo antibiotico ad attivit\u00e0 citostatica isolamento e propriet\u00e0","volume":"11","author":"Cassinelli","year":"1963","journal-title":"Giorn. Microbiol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0300","first-page":"109","article-title":"Descrizione e classificazione di un attinomicete (Streptomyces peucetius sp. nova) produttore di una sostanza ad attivit\u00e0 antitumorale: la Daunomicina","volume":"11","author":"Grein","year":"1963","journal-title":"Giorn. Microbiol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0305","first-page":"887","article-title":"Isolement d'un nouvel antibiotique dou\u00e9 d'activit\u00e9 antitumorale; la rubidomycine (13057 R.P.). Identit\u00e9 de la rubidomyocine et de la daunomycine. Colloque international sur la rubidomycine et la daunomycine. Paris. H\u00f4pital Saint-Louis, 11 Mars 1967","volume":"15","author":"Despois","year":"1967","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0310","first-page":"31","article-title":"Daunomycin: a new antibiotic with antitumor activity","volume":"38","author":"Di Marco","year":"1964","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0005-2787(65)90539-3","article-title":"On physico-chemical interactions between daunomycin and nucleic acids","volume":"103","author":"Calendi","year":"1965","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0320","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/bi00865a031","article-title":"Physicochemical properties of complexes between deoxyribonucleic acid and antibiotics which affect ribonucleic acid synthesis (actinomycin, daunomycin, cinerubin, nogalamycin, chormomycin, mithramycin, and olivomycin)","volume":"5","author":"Kersten","year":"1966","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0325","first-page":"39","article-title":"Activity of daunomycin, a new antitumor antibiotic, on normal and neoplastic cell growth in vitro","volume":"38","author":"Dimarco","year":"1964","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0330","first-page":"1","article-title":"Rubidomycin. Recent results","volume":"20","author":"Bernard","year":"1969","journal-title":"Cancer Res."},{"issue":"1966","key":"10.1016\/j.bcmd.2012.10.005_bb0335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(66)91751-X","article-title":"Rubidomycin A new agent active in the treatment of acute lymphoblatic leukemia","volume":"2","author":"Jacquillat","year":"1966","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0340","first-page":"951","article-title":"Essai de traitment des leuc\u00e9mies aigu\u00ebs lymphoblastiques et my\u00e9loblastiques par un antibiotique nouveau: La rubidomycine (13 057 RP). \u00c9tude de 61 observations","volume":"75","author":"Bernard","year":"1967","journal-title":"Presse Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0345","first-page":"949","article-title":"Accidents cardiaques observ\u00e9s au cours des traitments par la rubidomycine","volume":"15","author":"Macrez","year":"1967","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0350","first-page":"5a","article-title":"Rubidimycin (daunomycin) in the treatment of acute granulocytic leukemia, (A.G.L.)","volume":"9","author":"Bernard","year":"1968","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0355","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0140-6736(69)91296-3","article-title":"Daunorubicin in the treatment of acute myelocytic leukaemia","volume":"1","author":"Boiron","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0360","first-page":"339","article-title":"Treatment of acute granulocytic leukemias with daunomycin","volume":"5","author":"Groupe Cooperateur des l\u00e9ucemies et h\u00e9motosarcomes","year":"1969","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0365","first-page":"15a","article-title":"Comparative study of cytosine arabinoside (CA) therapy alone and combined with thioguanine (TG) mercaptopurine (MP or daunomycin (DN) in acute myelocytic leukemia (AML)","volume":"11","author":"Carey","year":"1970","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0370","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/bmj.4.5734.513","article-title":"Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia","volume":"4","author":"Crowther","year":"1970","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0375","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1600-0609.1972.tb00998.x","article-title":"Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination","volume":"9","author":"Brincker","year":"1972","journal-title":"Scand. J. Haematol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0380","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/1097-0142(197303)31:3<487::AID-CNCR2820310301>3.0.CO;2-U","article-title":"Combination chemotherapy with cytosine arabinoside and rubidomycin in 30 cases of acute granulocytic leukemia","volume":"31","author":"Gluckman","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0385","series-title":"Minutes of the Acute Leukemia Group B meeting, July 29, 1972","first-page":"22","article-title":"Comparison of intermittent Ara C + cyclophosphamide with Ara C + daunorubicin in induction and maintenance of untreated acute myelocytic leukemia","author":"Hoagland","year":"1972"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0390","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute non-lymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0395","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.V58.6.1203.1203","article-title":"Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B","volume":"58","author":"Rai","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0400","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2008-09-179341","article-title":"Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005","volume":"113","author":"Derolf","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0405","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0410","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3109\/14653249.2012.693744","article-title":"Dendritic cell vaccination in acute myeloid leukemia","volume":"14","author":"Anguille","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0415","doi-asserted-by":"crossref","first-page":"104926","DOI":"10.1155\/2011\/104926","article-title":"Recent advance in antigen-specific immunotherapy for acute myeloid leukemia","volume":"2011","author":"Kadowaki","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.stem.2011.08.006","article-title":"Leukemia stemness signatures step toward the clinic","volume":"9","author":"Becker","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0425","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.leukres.2012.02.022","article-title":"Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML","volume":"36","author":"Rosen","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0430","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2011-12-395335","article-title":"Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML","volume":"120","author":"Lo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0435","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1634\/stemcells.18-5-304","article-title":"Interrupting the inhibition of normal hematopoiesis in myelogenous leukemia: a hypothetical approach to therapy","volume":"18","author":"Lichtman","year":"2000","journal-title":"Stem Cells"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0440","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cellsig.2011.09.021","article-title":"Micro RNAs as a new therapeutic target towards leukaemia signaling","volume":"24","author":"Murray","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0445","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0450","unstructured":"C.T. Jordan, Personal communication. University of Rochester Medical Center. September 4, 2012."},{"key":"10.1016\/j.bcmd.2012.10.005_bb0455","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.2007-0228","article-title":"Battling the hematological malignancies: the 200 years' war","volume":"13","author":"Lichtman","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.bcmd.2012.10.005_bb0460","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMp1206643","article-title":"The calculus of national medical research policy-The United States versus Asia","volume":"367","author":"Sun","year":"2012","journal-title":"N. Engl. J. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961200191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961200191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:29:11Z","timestamp":1761049751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107997961200191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S107997961200191X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.10.005","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}